Activity Chair

Hope S. Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California San Francisco
Comprehensive Cancer Center
San Francisco, CA

Speakers Bureau: Genomic Health
Contracted Research (paid to institution): Amgen, BioMarin,
Eisai, Genentech/Roche, GlaxoSmithKline, Lilly, Macrogenics,
Merck, Novartis, OBI, Pfizer, Plexxikon


Joyce O'Shaughnessy, MD
Medical Director, US Oncology
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, TX

Consulting Fee: AbbVie, Arno, AstraZeneca, Celgene, Concept,
Eisai, Genentech, Lilly, Nektar, Novartis, Pfizer, Zymeworks

Debu Tripathy, MD
Professor and Chair, Department of Breast Medical Oncology
University of Texas MD Anderson Cancer Center
Houston, TX

Consulting Fee: Nektar Therapeutics, Novartis, Puma Biotechnology
Contracted Research (paid to institution): Novartis


Adam M. Brufsky, MD, PhD
Consulting Fee: Lilly, Pfizer


Vindico Medical Education Staff: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accredited By

This continuing medical education activity is provided by Vindico Medical Education

Activity Details

Credit Type: AMA PRA Category 1 Credit
Credit Amount: 1.0
Release Date: January 31, 2017
Expiration Date: January 30, 2018
Estimated Time to Complete Activity: 1 hour
Registration Required: No
Fee for Activity: There is no fee for participating in this activity.

Activity Description

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to improved treatment options, the 5-year survival rate for MBC remains poor. Fortunately, emerging agents, such as targeted therapies, including the novel class of cyclin-dependent kinase (CDK) 4/6 inhibitors, may improve outcomes for patients with MBC. This CME activity will review the mechanisms of action of new and emerging targeted therapies, as well as evaluate the latest clinical evidence regarding the safety, efficacy, and recommended usage of available and emerging CDK4/6 inhibitors for the management of MBC.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the mechanisms of action of new and emerging targeted therapies, including CDK4/6 inhibitors, for the treatment of MBC.
  • Evaluate the latest clinical evidence regarding the safety, efficacy, and recommended usage of available and emerging CDK4/6 inhibitors for the management of MBC.

Target Audience

The intended audience for the activity is oncologists and other health care professionals involved in the treatment of patients with metastatic breast cancer (MBC).

Requirements for Successful Completion

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Conflict of Interest Policy / Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Disclaimer Statement / Disclosure of Unlabeled Use

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions about the Activity

Contact us at

Hardware / Software Requirements

Our educational activities are available on Mac, PC, and Multi-Touch devices. For the best online experience, we recommend using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox or Safari.

Depending on your browser of choice, additional software, such as Adobe Reader®, may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.